Creso Pharma Limited

CPH

Creso Pharma Ltd. develops, registers and commercializes pharmaceutical-grade cannabis and hemp-hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health. The firm is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. The firm cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. (Mernova) and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc. (Halucenex), it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.

Hazer Group Limited

HZR

Hazer Group Ltd. engages in the research and development of novel graphite, and hydrogen production technology. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-12-02. The Company’s process enables the conversion of natural gas and similar feedstocks, into hydrogen and graphite, using iron ore as a process catalyst. Its Hazer Process focuses on savings for the hydrogen producer, as well as providing clean hydrogen with lower carbon dioxide emissions, enabling such hydrogen to be used in a range of developing clean energy applications, as well as in existing chemical processing industries. The HAZER Process produces synthetic graphite. The firm's markets include industrial hydrogen, hydrogen mobility and synthetic graphite. The company also has facilities, including a research and development lab and a fluid bed reactor pilot plant.

Mgc Pharmaceuticals Ltd

MXC

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-12-21. The firm is primarily focused on the development and supply of standardized phytomedicines to patients globally. The company has three clinical projects, as well as a pipeline of therapies: CimetrA, a Phase III symptomatic treatment for early COVID-19; CannEpil, a Phase IIb cannabis-based therapy for drug-resistant Epilepsy; CogniCann, in a Phase II trial for symptomatic relief of Dementia, and Irnican, a preclinical medicine to be used for treatment for Glioblastoma. The firm is focused on the ArtemiC range of products, and its cannabinoid products are primarily distributed within Australia, the United Kingdom and South America. The company has a product offering targeting two medical conditions, which include epilepsy and dementia. The firm's wholly owned subsidiaries include MGC Pharma (UK) Limited, MGC Research (Aus) Pty Ltd, and Medicinal Cannabis Clinics Pty Ltd.

4Ds Memory Limited

4DS

4DS Memory Ltd. operates as a semiconductor development company. The company is headquartered in Perth, Western Australia. The company went IPO on 2010-12-09. The firm is engaged in the development of a non-volatile memory technology known as Interface Switching resistive random-access memory (ReRAM), for gigabyte storage class memory. Interface Switching ReRAM, an area-based ReRAM technology positioned for storage class memory in mobile devices and cloud data centers. The company owns a patented Internet protocol (IP) portfolio, comprising 32 United States patents granted and an additional one patent application, which have been developed in-house to create high-density storage class memory. In collaboration with imec in Belgium, the Company is developing a production-compatible process for the 300-millimeter production tools that memory makers use to fabricate high-density, high-volume memories to use in a production-compatible process to build a 4DS megabit memory.